210
Participants
Start Date
August 10, 2022
Primary Completion Date
July 21, 2026
Study Completion Date
July 21, 2026
Belzutifan
40 mg tablet administered orally at a dose of 120 mg.
Palbociclib
75, 100, or 125 mg tablet administered orally according to randomized dose for 21 days consecutive days followed by 7 days off.
Macquarie University-MQ Health Clinical Trials Unit ( Site 2001), Macquarie University
Westmead Hospital ( Site 2006), Westmead
Frankston Hospital-Oncology and Haematology ( Site 2005), Frankston
One Clinical Research ( Site 2008), Nedlands
Georgetown University Medical Center ( Site 1002), Washington D.C.
University of Chicago Medical Center ( Site 1007), Chicago
Huntsman Cancer Institute-HCI Clinical Trials Office ( Site 1004), Salt Lake City
Emek Medical Center-oncology ( Site 3003), Afula
Rambam Health Care Campus-Oncology ( Site 3000), Haifa
Rabin Medical Center-Oncology ( Site 3004), Petah Tikva
Sourasky Medical Center ( Site 3005), Tel Aviv
Shaare Zedek Medical Center-Oncology ( Site 3002), Jerusalem
Beth Israel Deaconess Medical Center-Cancer Clinical Trials Office ( Site 1001), Boston
Merck Sharp & Dohme LLC
INDUSTRY